Literature DB >> 12684310

Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion.

Chi-Li Chung1, Yi-Chu Chen, Shi-Chuan Chang.   

Abstract

OBJECTIVE: To evaluate the effect of repeated thoracenteses on the fluid characteristics and the levels of various cytokines, including tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-5, IL-6, and IL-8, and of plasminogen activator inhibitor type 1 (PAI-1) and tissue type plasminogen activator in malignant pleural effusion and its clinical significance.
DESIGN: A prospective study. PATIENTS AND METHODS: Twenty-six patients with symptomatic and a large amount of free-flow malignant pleural effusions were studied. Thoracentesis with drainage of 500 mL of pleural fluid per day was performed for 3 continuous days (days 1 to 3). The effusion samples were collected to evaluate the changes of fluid characteristics, cytokine levels, and fibrinolytic activity. Chest ultrasonography was done on day 6 to observe the presence of fibrin strands. The result of pleurodesis was evaluated in the patients classified into groups based on chest ultrasonographic findings.
RESULTS: The values of TNF-alpha, PAI-1, IL-8, and neutrophil count in pleural fluid increased significantly during repeated thoracenteses in 26 patients studied. A positive correlation was found between the concentrations of TNF-alpha and PAI-1 and between the values of IL-8 and neutrophils. On day 6, fibrin strands were observed in the pleural effusion on chest ultrasonography in 11 patients (42%, fibrinous group) but were absent in the remaining 15 patients (nonfibrinous group). During repeated thoracenteses, a significant increase of effusion PAI-1 and TNF-alpha was observed in the fibrinous group but not in the nonfibrinous group. In addition, the levels of effusion PAI-1 and TNF-alpha obtained from day 2 and day 3 were significantly higher in the fibrinous group than in the nonfibrinous group. The success rate of pleurodesis was significantly higher in the fibrinous group (11 of 11 patients, 100%) than in the nonfibrinous group (8 of 12 patients, 67%).
CONCLUSIONS: Repeated thoracenteses may cause pleural inflammation and induce local release of proinflammatory cytokine as TNF-alpha, which may subsequently enhance the release of PAI-1 and lead to fibrin formation in malignant effusion. The presence of fibrin strands after repeated thoracenteses may be of considerable value in predicting the success of subsequent pleurodesis in patients with malignant pleural effusions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684310     DOI: 10.1378/chest.123.4.1188

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  15 in total

1.  Loculated transudative pleural effusion masquerading as right upper lobe consolidation in a haemodialysis patient.

Authors:  Sze Shyang Kho; Poh Sen Tay; Jun Lee; Siew Teck Tie
Journal:  AME Case Rep       Date:  2017-10-18

2.  Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion.

Authors:  Da-Wei Wu; Wei-An Chang; Kuan-Ting Liu; Meng-Chi Yen; Po-Lin Kuo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

3.  Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.

Authors:  Emile S Altmann; Iain Crossingham; Stephen Wilson; Huw R Davies
Journal:  Cochrane Database Syst Rev       Date:  2019-10-30

4.  Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.

Authors:  Ianko D Iankov; Cory Allen; Mark J Federspiel; Rae M Myers; Kah Whye Peng; James N Ingle; Stephen J Russell; Evanthia Galanis
Journal:  Mol Ther       Date:  2012-02-14       Impact factor: 11.454

Review 5.  Malignant pleural effusions: appropriate treatment approaches.

Authors:  Yener Aydin; Atila Turkyilmaz; Yavuz Selim Intepe; Atilla Eroglu
Journal:  Eurasian J Med       Date:  2009-12

6.  Does pleural fluid appearance really matter? The relationship between fluid appearance and cytology, cell counts, and chemical laboratory measurements in pleural effusions of patients with cancer.

Authors:  Bulent Ozcakar; Carlos H Martinez; Rodolfo C Morice; Georgie A Eapen; David Ost; Mona G Sarkiss; Hsienchang T Chiu; Carlos A Jimenez
Journal:  J Cardiothorac Surg       Date:  2010-08-18       Impact factor: 1.637

7.  Intrapleural adenoviral delivery of human plasminogen activator inhibitor-1 exacerbates tetracycline-induced pleural injury in rabbits.

Authors:  Sophia Karandashova; Galina Florova; Ali O Azghani; Andrey A Komissarov; Kathy Koenig; Torry A Tucker; Timothy C Allen; Kris Stewart; Amy Tvinnereim; Steven Idell
Journal:  Am J Respir Cell Mol Biol       Date:  2012-09-20       Impact factor: 6.914

8.  Pleural fluid osteopontin, vascular endothelial growth factor, and urokinase-type plasminogen activator levels as predictors of pleurodesis outcome and prognosticators in patients with malignant pleural effusion: a prospective cohort study.

Authors:  Li-Han Hsu; Pei-Chi Hsu; Tien-Ling Liao; An-Chen Feng; Nei-Min Chu; Shu-Huei Kao
Journal:  BMC Cancer       Date:  2016-07-13       Impact factor: 4.430

9.  Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.

Authors:  Audra J Schwalk; David E Ost; Sahara N Saltijeral; Henriette De La Garza; Roberto F Casal; Carlos A Jimenez; Georgie A Eapen; Jeff Lewis; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; Jack Lee; Yasir Elamin; Jianjun Zhang; Jack A Roth; Stephen Swisher; John V Heymach; Horiana B Grosu
Journal:  Chest       Date:  2020-11-17       Impact factor: 9.410

10.  Intrapleural fibrinolytic therapy (IPFT) in loculated pleural effusions--analysis of predictors for failure of therapy and bleeding: a cohort study.

Authors:  Saleh Abu-Daff; Donna E Maziak; Derar Alshehab; Jennifer Threader; Jelena Ivanovic; Valerie Deslaurier; Patrick-James Villeneuve; Sebastian Gilbert; Sudhir Sundaresan; Farid Shamji; Colleen Lougheed; Jean M Seely; Andrew J E Seely
Journal:  BMJ Open       Date:  2013-01-31       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.